CONTEMPORARY ASPECTS OF TREATMENT METASTATIC PROSTATE CANCER
Authors: A.K. Nosov, S.A. Reva, M.V. Berkut
Prostate cancer (PCa) is one of the leading causes of death from cancer in men. Violation of the cell life cycle is crucial for the development and progression of prostate cancer. Taxanes, including docetaxel and cabazitaxel, are microtubule stabilizing agents that block mitotic division and lead to apoptosis. Some past studies have shown relatively good tolerability of taxanes and promising efficacy in various regimens. In previous studies, an increase in the survival rate was observed with the use of taxanes in metastatic (both hormone-sensitive and castration-resistant) and mesoprotective (including as part of the combined treatment) process. This article describes modern approaches including new antiandrogenes to the use of this class of drugs in the treatment of metastatic prostate cancer.